Physician profile
David M Hopper
NPI 1861497455
$2,727.54
in general payments reported to CMS, 2019-2025
25 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $564 · 2021: $469 · 2022: $413 · 2023: $390 · 2024: $369 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $870.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,155.01 | 2019-2025 | Wegovy |
| Astrazeneca Pharmaceuticals Lp | $216.83 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.11 | 2019-2023 | |
| Abbvie INC. | $114.68 | 2021-2024 | |
| Pfizer INC. | $103.89 | 2019-2024 | |
| Amgen INC. | $96.99 | 2019-2024 | Otezla, Repatha |
| Exact Sciences Corporation | $89.24 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $83.16 | 2021-2023 | Shingrix, Arexvy |
| Amarin Pharma, INC. | $77.79 | 2019-2020 | |
| Dexcom, INC. | $70.83 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $70.71 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Lilly USA, LLC | $69.23 | 2021-2024 | Jardiance, Emgality |
| Abbott Laboratories | $60.94 | 2021-2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $45.50 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $41.98 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $39.66 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $37.61 | 2024 | Voquezna |
| Astellas Pharma US INC | $33.65 | 2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $32.69 | 2022-2023 | |
| Sanofi Pasteur INC. | $30.70 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.41 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $27.71 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $16.22 | 2020 | |
| Corcept Therapeutics | $15.16 | 2025 | Korlym |
| Eisai INC. | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hopper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.